Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

Key Points

• The research aims to investigate the incidence and severity of pruritus in melanoma patients receiving immune checkpoint inhibitor therapy and explore its potential mechanisms.
• Conducted a prospective analysis of melanoma patients undergoing immune checkpoint inhibitor treatment
• Monitored the occurrence of pruritus, irFatigue, and irRash
• Assessed the role of eosinophils in the pathomechanism of pruritus
• Pruritus is a prevalent side effect associated with immune checkpoint inhibitor therapy
• Significant correlations were found between pruritus, irFatigue, and irRash
• Further studies are necessary to understand the mechanisms and develop effective treatment protocols without compromising therapy efficacy